Alemtuzumab gets a license in Chile

A
Is early, effective, induction therapy the new treatment paradigm for MS? #MSBlog #MSResearch


“As promised the following are my slides from yesterday’s talk at the SINS meeting in Santiago, Chile. I was asked to talk on alemtuzumab as it has just been given a license in Chile with the same broad indication as that in Europe. Most of the Chilean MSologists I spoke to have a lot of experience using rituximab off-license so I don’t see any problems them using alemtuzumab in their current clinical practice.”




CoI: multiple

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

5 comments

  • How does rituximab off-license prepare them for alemtuzumab?
    Rituximab does not cause secondary autoimmunity

    • Re: "How does rituximab off-license prepare them for alemtuzumab?"

      We don't know they have never been compared head-2-head and we don't have phase 3 data on rituximab; only phase 2 data.

    • Re: "What is the connection between the Chilean MSologists rituximab experience and future alemtuzumab use>"

      Two reasons; (1) the fact that are prepared to use an induction-like agent (irreversible mode of action) to treat MS means they are psychologically prepared to use alemtuzumab; (2) the set-up for giving rituximab is similar to that what is required to use alemtuzumab.

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives